TEST:

Oncotype DX Breast Recurrence Score®Test

Despite these advancements, challenges persist in data heterogeneity and mechanistic interpretation of radiomic biomarkers. Emerging strategies integrating radiogenomic analyses and organoid validation platforms are establishing new paradigms for precision imaging-guided therapy.

P2, N=71, Completed, Asan Medical Center | Recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Aug 2026 --> Oct 2025

In both pre- and postmenopausal women, there is no difference in 10-year OS or LR between anastrozole and tamoxifen for BC patients with low Oncotype RS. We conclude that Stage 1-3, T1-T3 pre- and postmenopausal BC patients with Oncotype RS between 0 and 17 can safely choose either medication. This finding is of particular importance for premenopausal women who wish to avoid the adverse side effects of medically induced menopause and bone deterioration associated with the anastrozole and ovarian suppression approach.

The 21-gene RS of T1-3N1M0 breast cancer is related to tumor size, grade, ER, PR, and Ki-67 index. RS is an important factor affecting DM and DFS.

The prognostic value of RS in MBC appears evident; however, sex-specific thresholds may be necessary to optimize treatment stratification. Given current data limitations, male-inclusive clinical trials are needed to elucidate the predictive value of RS in men and improve personalized treatment strategies.

P3, N=1520, Not yet recruiting, West German Study Group

This observational study highlights that the Oncotype DX test supports therapeutic de-escalation in patients with RS ≤ 25 and serves as a prognostic marker. Oncogeriatric evaluations are essential to guide adjuvant treatments in older breast cancer patients prior to using genomic signatures.

Patients receiving chemotherapy had 21 (+91.3%) more hospital accesses, 115 (+101.8%) more health services and a reimbursement of €2811 (+31.5%) higher than patients not receiving chemotherapy (median values). Oncotype DX results in lower rates of chemotherapy prescription and in possible healthcare cost savings.

No clinically significant disparities were observed in race or income level in the application of the 21-gene recurrence score, which is reassuring, particularly as chemotherapy treatment regimens continue to trend appropriately trend toward de-escalation. However, underuse was more evident among older patients, separated/divorced/widowed individuals, and those undergoing mastectomy, highlighting opportunities to improve equity and adherence to guideline-based testing.

This systematic review and meta-analysis demonstrated that PORT is associated with improved OS in patients with EBC following BCS. However, certain clinicopathologic features, including age 65-70 years, progesterone receptor (-), luminal B subtype, triple-negative breast cancer, and low-risk 21-gene recurrence score, were identified as potential low-risk factors in patients who may be considered for PORT omission.

In the combined logistic regression analysis, the predicted AUC for RS >25 was 0.815 (P<0.001), with a sensitivity of 0.750 and a specificity of 0.803. The combined assessment of the PA using conventional US, UE, and CEUS holds significant value for preoperative evaluation and postoperative prognostic prediction.

This simplified algorithm accurately predicts Oncotype DX RS category using only histologic grade and PR%. It enables confident risk stratification in most patients without molecular testing, offering a low-cost, practical tool for clinical decision-making, particularly in resource-limited settings.